Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Polasek

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
European Journal of Clinical Pharmacology|June 24, 2014
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxinsKyra J Barnes, Andrew Rowland, Thomas M Polasek, et al.
Therapeutic Advances in Drug Safety|October 20, 2015
Pharmacists in Australian general practice: an opportunity for expertise in precision medicineThomas M Polasek, Andrew Rowland, Michael D Wiese, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitroThomas M Polasek, David J Elliot, Benjamin C Lewis, et al.
European Journal of Clinical Pharmacology|December 17, 2009
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3AThomas M Polasek, Janani S Sadagopal, David J Elliot, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 21, 2013
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosisMichael D Wiese, Andrew Rowland, Thomas M Polasek, et al.
Clinical Pharmacology and Therapeutics|August 1, 2024
Recent Advances Addressing the Challenges of Precision DosingIris K Minichmayr, Tomoyuki Mizuno, Srijib Goswami, et al.
British Journal of Clinical Pharmacology|January 13, 2011
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessmentThomas M Polasek, Frank P Y Lin, John O Miners, et al.
Frontiers in Genetics|January 24, 2025
Editorial: Pharmacogenetics of psychiatric disordersSarah Allegra, Silvia De Francia, Stefano Comità, et al.
Pharmacology & Therapeutics|June 1, 2023
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significanceJohn O Miners, Thomas M Polasek, Julie-Ann Hulin, et al.
BMC Bioinformatics|April 23, 2011
BICEPP: an example-based statistical text mining method for predicting the binary characteristics of drugsFrank P Y Lin, Stephen Anthony, Thomas M Polasek, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Clinical Pharmacology|June 24, 2014
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxinsKyra J Barnes, Andrew Rowland, Thomas M Polasek, et al.
Therapeutic Advances in Drug Safety|October 20, 2015
Pharmacists in Australian general practice: an opportunity for expertise in precision medicineThomas M Polasek, Andrew Rowland, Michael D Wiese, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitroThomas M Polasek, David J Elliot, Benjamin C Lewis, et al.
European Journal of Clinical Pharmacology|December 17, 2009
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3AThomas M Polasek, Janani S Sadagopal, David J Elliot, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 21, 2013
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosisMichael D Wiese, Andrew Rowland, Thomas M Polasek, et al.
Clinical Pharmacology and Therapeutics|August 1, 2024
Recent Advances Addressing the Challenges of Precision DosingIris K Minichmayr, Tomoyuki Mizuno, Srijib Goswami, et al.
British Journal of Clinical Pharmacology|January 13, 2011
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessmentThomas M Polasek, Frank P Y Lin, John O Miners, et al.
Frontiers in Genetics|January 24, 2025
Editorial: Pharmacogenetics of psychiatric disordersSarah Allegra, Silvia De Francia, Stefano Comità, et al.
Pharmacology & Therapeutics|June 1, 2023
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significanceJohn O Miners, Thomas M Polasek, Julie-Ann Hulin, et al.
BMC Bioinformatics|April 23, 2011
BICEPP: an example-based statistical text mining method for predicting the binary characteristics of drugsFrank P Y Lin, Stephen Anthony, Thomas M Polasek, et al.
Pageof 8